Skip to Main Content

Paper Details

Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.
Cancer Immunol Immunother
3
2023
EGFR, GBM, ICI, PD-1, PD-L1, brain cancer, glioblastoma, malignancies, patients, pembrolizumab, tumors
Author NameAffiliation
Kambiz NaelDavid Geffen School of Medicine at university of california los angeles
Nadejda M TsankovaIcahn School of Medicine at Mount Sinai
Nadejda M TsankovaIcahn School of Medicine at Mount Sinai
Robert Sebra
Robert SebraDepartment of Genetics and Genomic Sciences Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai New York
Robert Sebra
Robert SebraDepartment of Genetics and Genomic Sciences Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai New York
  • 1 - 7

Datasets

Release 1.2